Sterling Capital Management’s Definium Therapeutics DFTX Stock Holding History

Sterling Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.5K	Sell	457 -1,986	-81%	-$49.1K	﹤0.01%	1854
2026 Q1	$46.2K	Sell	2,443 -1,472	-38%	-$25K	﹤0.01%	1673
2025 Q4	$52.4K	Buy	3,915 +284	+8%	+$3.52K	﹤0.01%	1785
2025 Q3	$42.8K	Buy	3,631 +2,175	+149%	+$20.3K	﹤0.01%	1805
2025 Q2	$9.45K	Buy	1,456 +1,369	+1,574%	+$9K	﹤0.01%	2167
2025 Q1	$509	Buy	87 +13	+18%	+$93	﹤0.01%	2953
2024 Q4	$515	Hold	74	–	–	﹤0.01%	3030
2024 Q3	$421	Buy	+74	New	+$515	﹤0.01%	2936

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Sterling Capital Management's DFTX Position: Q2 2026 in Review

Sterling Capital Management reduced its Definium Therapeutics (DFTX) stake by 81% in Q2 2026, selling an estimated $49.1K and leaving 457 shares worth $21.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1854.

Sterling Capital Management first reported a position in DFTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $52.4K in Q4 2025. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Sterling Capital Management held 457 shares of Definium Therapeutics worth $21.5K as of Q2 2026.
Sterling Capital Management sold 1,986 Definium Therapeutics shares in Q2 2026, an estimated $49.1K.
Definium Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1854 holding.
Sterling Capital Management first reported a position in Definium Therapeutics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Definium Therapeutics position peaked at $52.4K in Q4 2025.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.